Dosage, titration, and gaps in treatment with extended release niacin in clinical practice

Current Medical Research and Opinion

Volumn 24, Issue 6, 2008, Pages 1817-1821

  Kamal Bahl, Sachin J ^a   Burke, Thomas A ^a   Watson, Douglas J ^a   Wentworth, Charles E ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Analytic Consulting Solutions   (United States)

Author keywords

Compliance; Coronary disease; Drug therapy; Hyperlipidemia; Niacin; Persistence

Indexed keywords

NICOTINIC ACID;

ADULT; CLINICAL PRACTICE; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DATA BASE; DOSE RESPONSE; DRUG DOSE TITRATION; HUMAN; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; PRESCRIPTION; RECOMMENDED DRUG DOSE; TREATMENT DURATION;

ADULT; ANTILIPEMIC AGENTS; COHORT STUDIES; DELAYED-ACTION PREPARATIONS; DYSLIPIDEMIAS; FEMALE; HUMANS; MALE; NIACIN; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT COMPLIANCE; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; TITRIMETRY;

EID: 46449105753     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802083408     Document Type: Conference Paper

References (16)

1. National Center for Health Statistics. Health, United States, 2005
2. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler Thromb Vasc Biol 2004;24:149-61
3. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005;45:185-97
4. McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med 2004;164:697-705
5. Goldberg AC. A meta-analysis of randomized controlled studies on the effects of extended-release niacin in women. Am J Cardiol 2004;94:121-4
6. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practice. Neth J Med 2004;62:229-34
7. NIASPAN®: Niacin extended-release tablets. Cranbury, NJ: Kos Pharmaceuticals, Inc., 2005
8. Goldberg AC. Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study. Am J Cardiol 1998;82:35-8U; discussion 9-41U
9. Goldberg A, Alagona P, Jr, Capuzzi DM, et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol 2000;85:1100-5
10. Hiatt JG, Shamsie SG, Schectman G. Discontinuation rates of cholesterol-lowering medications: implications for primary care. Am J Manag Care 1999;5:437-44
11. Guyton JR, Goldberg AC, Kreisberg RA, et al. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol 1998;82:737-43
12. Capuzzi DM, Guyton JR, Morgan JM, et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol 1998;82:74-81U; discussion 5-6U
13. Marcelino JJ, Feingold KR. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med 1996;100:605-10
14. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-67
15. Latts LM. Assessing the results: phase 1 hyperlipidemia outcomes in 27 health plans. Am J Med 2001;110(Suppl 6A):17-23S
16. Stone NJ, Bilek S, Rosenbaum S. Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options. Am J Cardiol 2005;96:53-9E